Medtronic (BSP:MDTC34) Beneish M-Score: -2.58 (As of Jun. 25, 2026)


BSP:MDTC34 Medtronic PLC BSP:MDTC34
67 GF Score
Price R$209.95
GF Value R$260.36
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medtronic Beneish M-Score?

Medtronic BSP:MDTC34 +2.96% 67 Beneish M-Score is -2.58 as of Jun. 25, 2026. GuruFocus rates BSP:MDTC34 with a GF Score™ of 67/100 and a GF Value™ of R$260.36 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Medtronic ranks worse than 50.52% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Medtronic's Beneish M-Score or its related term are showing as below:

BSP:MDTC34' s Beneish M-Score Range Over the Past 10 Years
Min: -2.82   Med: -2.58   Max: -2.44
Current: -2.58

During the past 13 years, the highest Beneish M-Score of Medtronic was -2.44. The lowest was -2.82. And the median was -2.58.


Medtronic Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Medtronic's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtronic Beneish M-Score Chart

Medtronic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 -2.51 -2.64 -2.57 -2.58

Medtronic Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 -2.57 -2.58 -2.58 -2.58

BSP:MDTC34 vs SYK, BSX, EW: Beneish M-Score Comparison

For the Medical Devices subindustry, Medtronic's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medtronic Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Medtronic's Beneish M-Score falls into.


BSP:MDTC34
67GF Score
Medtronic PLC BSP:MDTC34
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtronic Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Medtronic for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8844+0.528 * 1.0048+0.404 * 0.9822+0.892 * 1.0023+0.115 * 0.9893
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0028+4.679 * -0.028143-0.327 * 0.9679
=-2.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Apr26) TTM:Last Year (Apr25) TTM:
Total Receivables was R$33,440 Mil.
Revenue was 49367.457 + 48075.037 + 48238.855 + 47463.79 = R$193,145 Mil.
Gross Profit was 32262.265 + 30688.69 + 31760.88 + 30858.656 = R$125,570 Mil.
Total Current Assets was R$124,775 Mil.
Total Assets was R$468,294 Mil.
Property, Plant and Equipment(Net PPE) was R$37,336 Mil.
Depreciation, Depletion and Amortization(DDA) was R$15,747 Mil.
Selling, General, & Admin. Expense(SGA) was R$62,636 Mil.
Total Current Liabilities was R$58,685 Mil.
Long-Term Debt & Capital Lease Obligation was R$131,752 Mil.
Net Income was 6262.172 + 6094.019 + 7396.517 + 5754.528 = R$25,507 Mil.
Non Operating Income was -25.169 + -95.969 + 441.422 + -215.795 = R$104 Mil.
Cash Flow from Operations was 12952.225 + 14629.91 + 4979.46 + 6020.122 = R$38,582 Mil.
Total Receivables was R$37,725 Mil.
Revenue was 51691.794 + 49842.383 + 47290.403 + 43879.177 = R$192,704 Mil.
Gross Profit was 33469.09 + 33138.092 + 30710.905 + 28572.745 = R$125,891 Mil.
Total Current Assets was R$137,895 Mil.
Total Assets was R$530,873 Mil.
Property, Plant and Equipment(Net PPE) was R$39,590 Mil.
Depreciation, Depletion and Amortization(DDA) was R$16,444 Mil.
Selling, General, & Admin. Expense(SGA) was R$62,316 Mil.
Total Current Liabilities was R$74,576 Mil.
Long-Term Debt & Capital Lease Obligation was R$148,480 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(33440.198 / 193145.139) / (37725.108 / 192703.757)
=0.173135 / 0.195767
=0.8844

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(125890.832 / 192703.757) / (125570.491 / 193145.139)
=0.653287 / 0.650135
=1.0048

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (124775.279 + 37336.436) / 468293.649) / (1 - (137894.967 + 39589.649) / 530873.04)
=0.653825 / 0.665674
=0.9822

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=193145.139 / 192703.757
=1.0023

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(16444.237 / (16444.237 + 39589.649)) / (15746.958 / (15746.958 + 37336.436))
=0.29347 / 0.296646
=0.9893

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(62636.189 / 193145.139) / (62316.409 / 192703.757)
=0.324296 / 0.323379
=1.0028

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((131752.265 + 58685.206) / 468293.649) / ((148480.001 + 74575.85) / 530873.04)
=0.406663 / 0.420168
=0.9679

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(25507.236 - 104.489 - 38581.717) / 468293.649
=-0.028143

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Medtronic has a M-score of -2.71 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.58 mean?
Medtronic (BSP:MDTC34) has a Beneish M-Score of -2.58 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Medtronic and its competitors. According to the industry distribution chart, Medtronic ranks #387 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 50.5%.
Is Medtronic's Beneish M-Score too high?
Medtronic's current Beneish M-Score is -2.58. Based on the distribution chart, Medtronic ranks #387 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medtronic has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's Beneish M-Score compare to SYK and BSX?
According to the Medical Devices & Instruments industry distribution chart, Medtronic ranks #387 out of 766 companies for Beneish M-Score. This places Medtronic in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Medtronic and its competitors. Medtronic's current Beneish M-Score is -2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (BSP:MDTC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$260.36, compared to a current price of R$209.95 — trading 19.4% below its estimated fair value. The current Beneish M-Score is -2.58. Medtronic's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Medtronic (BSP:MDTC34), the current Beneish M-Score is -2.58 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medtronic (BSP:MDTC34) Overvalued in 2026?

Based on GuruFocus' analysis, Medtronic stock appears to be undervalued. The current stock price of R$209.95 is trading 19.4% below its estimated GF Value™ of R$260.36. GuruFocus considers Medtronic to be Modestly Undervalued.

Key valuation signals for BSP:MDTC34:

  • Beneish M-Score: -2.58
  • GF Value™: R$260.36 vs. price of R$209.95 (19.4% below fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the BSP:MDTC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medtronic Business Description

Address Parkmore Business Park West, Building Two, Galway, IRL
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
67GF Score

Get the complete analysis for BSP:MDTC34

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$209.95
Price
R$260.36
GF Value